schliessen

Filtern

 

Bibliotheken

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two... Full description

Journal Title: The Lancet (British edition) 2013, Vol.382 (9893), p.700-708
Main Author: Cahn, Pedro, Dr
Other Authors: Pozniak, Anton L, MD , Mingrone, Horacio, MD , Shuldyakov, Andrey, MD , Brites, Carlos, MD , Andrade-Villanueva, Jaime F, MD , Richmond, Gary, MD , Buendia, Carlos Beltran, MD , Fourie, Jan, MD , Ramgopal, Moti, MD , Hagins, Debbie, MD , Felizarta, Franco, MD , Madruga, Jose, MD , Reuter, Tania, MD , Newman, Tamara, MD , Small, Catherine B, MD , Lombaard, John, MD , Grinsztejn, Beatriz, MD , Dorey, David, MMath , Underwood, Mark, PhD , Griffith, Sandy, PharmD , Min, Sherene, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
HIV
RNA
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1566858956
title: Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
format: Article
creator:
  • Cahn, Pedro, Dr
  • Pozniak, Anton L, MD
  • Mingrone, Horacio, MD
  • Shuldyakov, Andrey, MD
  • Brites, Carlos, MD
  • Andrade-Villanueva, Jaime F, MD
  • Richmond, Gary, MD
  • Buendia, Carlos Beltran, MD
  • Fourie, Jan, MD
  • Ramgopal, Moti, MD
  • Hagins, Debbie, MD
  • Felizarta, Franco, MD
  • Madruga, Jose, MD
  • Reuter, Tania, MD
  • Newman, Tamara, MD
  • Small, Catherine B, MD
  • Lombaard, John, MD
  • Grinsztejn, Beatriz, MD
  • Dorey, David, MMath
  • Underwood, Mark, PhD
  • Griffith, Sandy, PharmD
  • Min, Sherene, MD
subjects:
  • Abridged Index Medicus
  • Adult
  • adults
  • antiretroviral agents
  • diarrhea
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug dosages
  • drug resistance
  • Drug Resistance, Viral
  • Drug therapy
  • drugs
  • Female
  • headache
  • health services
  • Heterocyclic Compounds, 3-Ring - administration & dosage
  • Heterocyclic Compounds, 3-Ring - adverse effects
  • HIV
  • HIV infection
  • HIV Infections - drug therapy
  • HIV Integrase Inhibitors - administration & dosage
  • HIV Integrase Inhibitors - adverse effects
  • HIV-1
  • Human immunodeficiency virus
  • Human immunodeficiency virus 1
  • Humans
  • Internal Medicine
  • Male
  • Middle Aged
  • Mutation
  • Patient safety
  • patients
  • Plasma
  • Pyrrolidinones - administration & dosage
  • Pyrrolidinones - adverse effects
  • Raltegravir Potassium
  • respiratory tract diseases
  • RNA
  • RNA, Viral - metabolism
  • screening
  • therapeutics
  • Treatment Outcome
  • Viral Load
ispartof: The Lancet (British edition), 2013, Vol.382 (9893), p.700-708
description: Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov , NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both group
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8015702
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1566858956
sourceformatXML
sourcesystemPC
galeidA345977858
sourcerecordidA345977858
originalsourceidFETCH-LOGICAL-1689t-b09ddc6ca50c2cee37ff50cabb708a1608d578093c7181d7f11897866a6c94a03
addsrcrecordideNqNku9P1DAYxxejEUT_BHWJbzBh2K7rj2GiIahwCdEXiPFd03XP7gq7Ftvu8P41_zq7OwQhJpgl29p-nk_7bN8se47RLkaYvTlBuEIF44RtY_Ka4bLEBXqQbeKKVwWt-PeH2eY1spE9CeEMIVQxRB9nGyURBBFKN7NfH1w_RJh6tTA-X4APQ8i96q-njM2VjcZD9C6NVV_AzwvwBqyGdictr8gAhbEz05jofGGVWUCu2qGPIb80cZYfTb7t5ZcA53klcg9htdJ5N8_jDNJ2tnVzE0Zf64amh6LpjU0j62zydmk7501c5if7k-PJ58M8xKFdPs0edaoP8OzquZWdfvr49eCoOP5yODnYPy4wE3UsGlS3rWZaUaRLDUB416VX1TQcCYUZEi3lAtVEcyxwyzuMRc0FY4rpulKIbGXba--Fdz8GCFGms2roe2XBDUFiypigoqbsfrQidYkZp_V_oKUoOaoET-irO-iZG7xNPY8UJzg1im6oqepBpq_mold6lMp9UtGa83TIRO3-g0pXC3OjnYXOpPlbBTt_FTRDMBZCugUzncUwVUMIt3G6xrV3IXjo5IU3c-WXEiM5BleugivHVEpM5Cq4cjz9i6seh2YO7XXVn6Qm4O0dsTZRReNsasD09-pfrqs75aSaehPk6UmJMEUIJ39FEvF-TUCK0sKAl0GvQ56yr6Nsnbl3j3d3DDql2GjVn8MSws0_k6GUaC0ZHZisDIj8Bp4NLZI
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1427311680
display
typearticle
titleDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
sourceAlma/SFX Local Collection
creatorCahn, Pedro, Dr ; Pozniak, Anton L, MD ; Mingrone, Horacio, MD ; Shuldyakov, Andrey, MD ; Brites, Carlos, MD ; Andrade-Villanueva, Jaime F, MD ; Richmond, Gary, MD ; Buendia, Carlos Beltran, MD ; Fourie, Jan, MD ; Ramgopal, Moti, MD ; Hagins, Debbie, MD ; Felizarta, Franco, MD ; Madruga, Jose, MD ; Reuter, Tania, MD ; Newman, Tamara, MD ; Small, Catherine B, MD ; Lombaard, John, MD ; Grinsztejn, Beatriz, MD ; Dorey, David, MMath ; Underwood, Mark, PhD ; Griffith, Sandy, PharmD ; Min, Sherene, MD
creatorcontribCahn, Pedro, Dr ; Pozniak, Anton L, MD ; Mingrone, Horacio, MD ; Shuldyakov, Andrey, MD ; Brites, Carlos, MD ; Andrade-Villanueva, Jaime F, MD ; Richmond, Gary, MD ; Buendia, Carlos Beltran, MD ; Fourie, Jan, MD ; Ramgopal, Moti, MD ; Hagins, Debbie, MD ; Felizarta, Franco, MD ; Madruga, Jose, MD ; Reuter, Tania, MD ; Newman, Tamara, MD ; Small, Catherine B, MD ; Lombaard, John, MD ; Grinsztejn, Beatriz, MD ; Dorey, David, MMath ; Underwood, Mark, PhD ; Griffith, Sandy, PharmD ; Min, Sherene, MD ; on behalf of the extended SAILING Study Team ; extended SAILING Study Team
descriptionSummary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov , NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(13)61221-0
3PMID: 23830355
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Adult ; adults ; antiretroviral agents ; diarrhea ; Double-Blind Method ; Drug Administration Schedule ; Drug dosages ; drug resistance ; Drug Resistance, Viral ; Drug therapy ; drugs ; Female ; headache ; health services ; Heterocyclic Compounds, 3-Ring - administration & dosage ; Heterocyclic Compounds, 3-Ring - adverse effects ; HIV ; HIV infection ; HIV Infections - drug therapy ; HIV Integrase Inhibitors - administration & dosage ; HIV Integrase Inhibitors - adverse effects ; HIV-1 ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; Internal Medicine ; Male ; Middle Aged ; Mutation ; Patient safety ; patients ; Plasma ; Pyrrolidinones - administration & dosage ; Pyrrolidinones - adverse effects ; Raltegravir Potassium ; respiratory tract diseases ; RNA ; RNA, Viral - metabolism ; screening ; therapeutics ; Treatment Outcome ; Viral Load
ispartofThe Lancet (British edition), 2013, Vol.382 (9893), p.700-708
rights
0Elsevier Ltd
12013 Elsevier Ltd
2Copyright © 2013 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2013 Elsevier B.V.
4Copyright Elsevier Limited Aug 24, 2013
lds50peer_reviewed
citedbyFETCH-LOGICAL-1689t-b09ddc6ca50c2cee37ff50cabb708a1608d578093c7181d7f11897866a6c94a03
citesFETCH-LOGICAL-1689t-b09ddc6ca50c2cee37ff50cabb708a1608d578093c7181d7f11897866a6c94a03
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://agris.fao.org/agris-search/search.do?recordID=US201500130343$$DView record in FAO AGRIS
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23830355$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Cahn, Pedro, Dr
1Pozniak, Anton L, MD
2Mingrone, Horacio, MD
3Shuldyakov, Andrey, MD
4Brites, Carlos, MD
5Andrade-Villanueva, Jaime F, MD
6Richmond, Gary, MD
7Buendia, Carlos Beltran, MD
8Fourie, Jan, MD
9Ramgopal, Moti, MD
10Hagins, Debbie, MD
11Felizarta, Franco, MD
12Madruga, Jose, MD
13Reuter, Tania, MD
14Newman, Tamara, MD
15Small, Catherine B, MD
16Lombaard, John, MD
17Grinsztejn, Beatriz, MD
18Dorey, David, MMath
19Underwood, Mark, PhD
20Griffith, Sandy, PharmD
21Min, Sherene, MD
22on behalf of the extended SAILING Study Team
23extended SAILING Study Team
title
0Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov , NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare.
subject
0Abridged Index Medicus
1Adult
2adults
3antiretroviral agents
4diarrhea
5Double-Blind Method
6Drug Administration Schedule
7Drug dosages
8drug resistance
9Drug Resistance, Viral
10Drug therapy
11drugs
12Female
13headache
14health services
15Heterocyclic Compounds, 3-Ring - administration & dosage
16Heterocyclic Compounds, 3-Ring - adverse effects
17HIV
18HIV infection
19HIV Infections - drug therapy
20HIV Integrase Inhibitors - administration & dosage
21HIV Integrase Inhibitors - adverse effects
22HIV-1
23Human immunodeficiency virus
24Human immunodeficiency virus 1
25Humans
26Internal Medicine
27Male
28Middle Aged
29Mutation
30Patient safety
31patients
32Plasma
33Pyrrolidinones - administration & dosage
34Pyrrolidinones - adverse effects
35Raltegravir Potassium
36respiratory tract diseases
37RNA
38RNA, Viral - metabolism
39screening
40therapeutics
41Treatment Outcome
42Viral Load
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNqNku9P1DAYxxejEUT_BHWJbzBh2K7rj2GiIahwCdEXiPFd03XP7gq7Ftvu8P41_zq7OwQhJpgl29p-nk_7bN8se47RLkaYvTlBuEIF44RtY_Ka4bLEBXqQbeKKVwWt-PeH2eY1spE9CeEMIVQxRB9nGyURBBFKN7NfH1w_RJh6tTA-X4APQ8i96q-njM2VjcZD9C6NVV_AzwvwBqyGdictr8gAhbEz05jofGGVWUCu2qGPIb80cZYfTb7t5ZcA53klcg9htdJ5N8_jDNJ2tnVzE0Zf64amh6LpjU0j62zydmk7501c5if7k-PJ58M8xKFdPs0edaoP8OzquZWdfvr49eCoOP5yODnYPy4wE3UsGlS3rWZaUaRLDUB416VX1TQcCYUZEi3lAtVEcyxwyzuMRc0FY4rpulKIbGXba--Fdz8GCFGms2roe2XBDUFiypigoqbsfrQidYkZp_V_oKUoOaoET-irO-iZG7xNPY8UJzg1im6oqepBpq_mold6lMp9UtGa83TIRO3-g0pXC3OjnYXOpPlbBTt_FTRDMBZCugUzncUwVUMIt3G6xrV3IXjo5IU3c-WXEiM5BleugivHVEpM5Cq4cjz9i6seh2YO7XXVn6Qm4O0dsTZRReNsasD09-pfrqs75aSaehPk6UmJMEUIJ39FEvF-TUCK0sKAl0GvQ56yr6Nsnbl3j3d3DDql2GjVn8MSws0_k6GUaC0ZHZisDIj8Bp4NLZI
startdate2013
enddate2013
creator
0Cahn, Pedro, Dr
1Pozniak, Anton L, MD
2Mingrone, Horacio, MD
3Shuldyakov, Andrey, MD
4Brites, Carlos, MD
5Andrade-Villanueva, Jaime F, MD
6Richmond, Gary, MD
7Buendia, Carlos Beltran, MD
8Fourie, Jan, MD
9Ramgopal, Moti, MD
10Hagins, Debbie, MD
11Felizarta, Franco, MD
12Madruga, Jose, MD
13Reuter, Tania, MD
14Newman, Tamara, MD
15Small, Catherine B, MD
16Lombaard, John, MD
17Grinsztejn, Beatriz, MD
18Dorey, David, MMath
19Underwood, Mark, PhD
20Griffith, Sandy, PharmD
21Min, Sherene, MD
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0FBQ
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
sort
creationdate2013
titleDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
authorCahn, Pedro, Dr ; Pozniak, Anton L, MD ; Mingrone, Horacio, MD ; Shuldyakov, Andrey, MD ; Brites, Carlos, MD ; Andrade-Villanueva, Jaime F, MD ; Richmond, Gary, MD ; Buendia, Carlos Beltran, MD ; Fourie, Jan, MD ; Ramgopal, Moti, MD ; Hagins, Debbie, MD ; Felizarta, Franco, MD ; Madruga, Jose, MD ; Reuter, Tania, MD ; Newman, Tamara, MD ; Small, Catherine B, MD ; Lombaard, John, MD ; Grinsztejn, Beatriz, MD ; Dorey, David, MMath ; Underwood, Mark, PhD ; Griffith, Sandy, PharmD ; Min, Sherene, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1689t-b09ddc6ca50c2cee37ff50cabb708a1608d578093c7181d7f11897866a6c94a03
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Abridged Index Medicus
1Adult
2adults
3antiretroviral agents
4diarrhea
5Double-Blind Method
6Drug Administration Schedule
7Drug dosages
8drug resistance
9Drug Resistance, Viral
10Drug therapy
11drugs
12Female
13headache
14health services
15Heterocyclic Compounds, 3-Ring - administration & dosage
16Heterocyclic Compounds, 3-Ring - adverse effects
17HIV
18HIV infection
19HIV Infections - drug therapy
20HIV Integrase Inhibitors - administration & dosage
21HIV Integrase Inhibitors - adverse effects
22HIV-1
23Human immunodeficiency virus
24Human immunodeficiency virus 1
25Humans
26Internal Medicine
27Male
28Middle Aged
29Mutation
30Patient safety
31patients
32Plasma
33Pyrrolidinones - administration & dosage
34Pyrrolidinones - adverse effects
35Raltegravir Potassium
36respiratory tract diseases
37RNA
38RNA, Viral - metabolism
39screening
40therapeutics
41Treatment Outcome
42Viral Load
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Cahn, Pedro, Dr
1Pozniak, Anton L, MD
2Mingrone, Horacio, MD
3Shuldyakov, Andrey, MD
4Brites, Carlos, MD
5Andrade-Villanueva, Jaime F, MD
6Richmond, Gary, MD
7Buendia, Carlos Beltran, MD
8Fourie, Jan, MD
9Ramgopal, Moti, MD
10Hagins, Debbie, MD
11Felizarta, Franco, MD
12Madruga, Jose, MD
13Reuter, Tania, MD
14Newman, Tamara, MD
15Small, Catherine B, MD
16Lombaard, John, MD
17Grinsztejn, Beatriz, MD
18Dorey, David, MMath
19Underwood, Mark, PhD
20Griffith, Sandy, PharmD
21Min, Sherene, MD
22on behalf of the extended SAILING Study Team
23extended SAILING Study Team
collection
0AGRIS
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Cahn, Pedro, Dr
1Pozniak, Anton L, MD
2Mingrone, Horacio, MD
3Shuldyakov, Andrey, MD
4Brites, Carlos, MD
5Andrade-Villanueva, Jaime F, MD
6Richmond, Gary, MD
7Buendia, Carlos Beltran, MD
8Fourie, Jan, MD
9Ramgopal, Moti, MD
10Hagins, Debbie, MD
11Felizarta, Franco, MD
12Madruga, Jose, MD
13Reuter, Tania, MD
14Newman, Tamara, MD
15Small, Catherine B, MD
16Lombaard, John, MD
17Grinsztejn, Beatriz, MD
18Dorey, David, MMath
19Underwood, Mark, PhD
20Griffith, Sandy, PharmD
21Min, Sherene, MD
aucorp
0on behalf of the extended SAILING Study Team
1extended SAILING Study Team
formatjournal
genrearticle
ristypeJOUR
atitleDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
jtitleThe Lancet (British edition)
addtitleLancet
date2013
risdate2013
volume382
issue9893
spage700
epage708
pages700-708
issn0140-6736
eissn1474-547X
codenLANCAO
noteshttp://dx.doi.org/10.1016/S0140-6736(13)61221-0
abstractSummary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. Methods ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, active-controlled, non-inferiority study that began in October, 2010. Eligible patients had two consecutive plasma HIV-1 RNA assessments of 400 copies per mL or higher (unless >1000 copies per mL at screening), resistance to two or more classes of antiretroviral drugs, and had one to two fully active drugs for background therapy. Participants were randomly assigned (1:1) to once-daily dolutegravir 50 mg or twice-daily raltegravir 400 mg, with investigator-selected background therapy. Matching placebo was given, and study sites were masked to treatment assignment. The primary endpoint was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48, evaluated in all participants randomly assigned to treatment groups who received at least one dose of study drug, excluding participants at one site with violations of good clinical practice. Non-inferiority was prespecified with a 12% margin; if non-inferiority was established, then superiority would be tested per a prespecified sequential testing procedure. A key prespecified secondary endpoint was the proportion of patients with treatment-emergent integrase-inhibitor resistance. The trial is registered at ClinicalTrials.gov , NCT01231516. Findings Analysis included 715 patients (354 dolutegravir; 361 raltegravir). At week 48, 251 (71%) patients on dolutegravir had HIV-1 RNA less than 50 copies per mL versus 230 (64%) patients on raltegravir (adjusted difference 7·4%, 95% CI 0·7 to 14·2); superiority of dolutegravir versus raltegravir was then concluded (p=0·03). Significantly fewer patients had virological failure with treatment-emergent integrase-inhibitor resistance on dolutegravir (four vs 17 patients; adjusted difference −3·7%, 95% CI −6·1 to −1·2; p=0·003). Adverse event frequencies were similar across groups; the most commonly reported events for dolutegravir versus raltegravir were diarrhoea (71 [20%] vs 64 [18%] patients), upper respiratory tract infection (38 [11%] vs 29 [8%]), and headache (33 [9%] vs 31 [9%]). Safety events leading to discontinuation were infrequent in both groups (nine [3%] dolutegravir, 14 [4%] raltegravir). Interpretation Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravir in this treatment-experienced patient group. Funding ViiV Healthcare.
copEngland
pubElsevier Ltd
pmid23830355
doi10.1016/S0140-6736(13)61221-0